Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Galapagos NV ADR (GLPG)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Galapagos ADR's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
29.34 +0.89    +3.13%
16:00:01 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 149,745
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 28.30 - 29.44
Galapagos ADR 29.34 +0.89 +3.13%

Galapagos NV ADR Company Profile

 
Get an in-depth profile of Galapagos NV ADR, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

1338

Equity Type

ADR

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Contact Information

Address Generaal De Wittelaan L11 A3
Mechelen, 2800
Belgium
Phone 32 1 534 29 00
Fax 32 1 534 29 01
Web www.glpg.com

Top Executives

Name Age Since Title
Paulus A. Stoffels 61 2022 CEO, Chairman, Interim Head of R&D
Jerome Contamine 66 2022 Lead Independent Non-Executive Director
Elisabeth Svanberg 62 2020 Independent Non-Executive Director
Peter Guenter 61 2019 Independent Non-Executive Director
Simon J. Sturge 65 2023 Independent Non-Executive Director
Andrew D. Dickinson 54 2024 Non-Executive Non-Independent Director
Linda Slanec Higgins 62 2019 Non-Executive Non-Independent Director
Susanne Schaffert 57 2023 Non-Executive Independent Director
Daniel G. Baker 74 2022 Non-Executive Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

GLPG Comments

Write your thoughts about Galapagos NV ADR
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Rahmi Pidie
Rahmi Pidie Apr 03, 2022 6:25AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
sell
Reply
0 0
Report
Bart Van Der Zanden
Bart Van Der Zanden Apr 26, 2021 10:23AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
buy now?
Reply
1 0
Report
Maya Normusbut
Maya Normusbut Feb 11, 2021 8:45AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
they have 5 bil in cash. Cashburn should be -10% annually. + sales filgotinib + pipeline speculations + new aquired businesses (they are looking to take over other companies with revenu)  . i think this is way oversold.
Reply
6 1
Report
Eren Eren
Eren Eren Feb 11, 2021 8:45AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Look where we are now.... what do you think 🤪
Reply
0 0
Report
Dümaine Hinds
Kingshad Feb 11, 2021 4:05AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
long-term head and shoulder pattern
Reply
5 0
Report
Tomer Brosh
Tomer Brosh Feb 10, 2021 5:51PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
dead?
Reply
0 3
Report
Commodity Trader
Commodity Trader Feb 10, 2021 10:23AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
GALAPAGOS is what we will see for all the markets soon, maybe end 21 but it will all come down
Reply
1 6
Report
Job Losm
Job Losm Feb 10, 2021 10:23AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
whats's your prediction?
Reply
0 0
Report
Lars Holland
Lars Holland Oct 30, 2020 5:39PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Galapagos Enters November With Flair: New Revelation About Toledo Target Family https://pennystocks.news/galapagos-enters-november-with-flair-new-revelation-about-toledo-target-family-glpg/
Reply
0 0
Report
mollow itz
mollow itz Jul 24, 2020 9:02AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/gilead-and-galapagos-announce-positive-european-chmp-opinion-for-jyseleca-filgotinib-for-the-treatment-of-adults-with-moderate-to-severe-rheumatoid
Reply
1 0
Report
Paul Verh
Paul Verh May 24, 2020 5:41AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Investor overreaction though. Besides, the main application of Filgotinib is not for ulcerative colitis (turnover approximately EUR 500 million) but for rheumatism (turnover EUR 5 BILLION). Great starting moment now.
Reply
2 0
Report
Maurice Fortune
Maurice Fortune Sep 10, 2019 12:37PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
What does galapagos do?
Reply
3 0
Report
Rudi Lenie
Rudi Lenie Sep 10, 2019 12:37PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
no google in your country?
Reply
5 4
Report
Coffee Man
Coffee Man Sep 10, 2019 12:37PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Rudi Lenie  Google so hard... Investing.com so easy to get answer. Me no need to think
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email